文献速递肝病消化道肿瘤与早癌

2型糖尿病住院患者肝病进展负担研究

Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
PubMed 文献 · J Hepatol · 2021-10-02

该回顾性双中心纵向队列纳入2010-2020年52,066例2型糖尿病住院患者,量化肝病进展至肝细胞癌和/或失代偿期肝硬化的负担。酒精使用障碍占肝相关并发症的57%,其归因分数为55%,而肥胖归因分数仅7%;2型糖尿病控制与肝病进展无关。

要点

  • 酒精使用障碍是2型糖尿病患者肝病进展的主要归因因素,归因分数达55%。
  • 非代谢性肝相关危险因素占肝病负担的37%,肥胖归因分数为7%。
  • 2型糖尿病控制程度与肝病进展无关联。

核心结论

  • 在2型糖尿病住院患者中,酒精使用障碍而非肥胖贡献了大部分肝病负担,建议患者尽量少饮酒。

研究设计与样本

  • 2010-2020年回顾性、双中心、纵向队列,纳入52,066例2型糖尿病住院患者,中位年龄64±14岁,58%为男性。

主要发现

  • 肝相关并发症发生率为3.9(95%CI 3.5-4.3)/1000人年,竞争性死亡发生率为27.8(95%CI 26.7-28.9)/1000人年。
  • 酒精使用障碍占肝相关并发症的57%,非代谢性肝相关危险因素占37%。
  • 肝病进展的调整风险比:酒精相关肝病55.7(95%CI 40.5-76.6),无酒精相关肝病的酒精使用障碍3.5(95%CI 2.3-5.2),非代谢性肝相关危险因素8.9(95%CI 6.9-11.5),肥胖1.5(95%CI 1.1-2.1)。
  • 酒精使用障碍、非代谢性肝相关危险因素和肥胖对肝病负担的归因分数分别为55%、14%和7%。
  • 肥胖患者肝细胞癌发生率为0.3(95%CI 0.1-0.5)/1000人年,且随年龄增长而升高。

临床怎么用

  • 对2型糖尿病患者应建议尽量少饮酒,以降低肝病进展风险。
  • 应评估2型糖尿病患者的酒精使用障碍及非代谢性肝相关危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are uncertainties regarding the burden of liver disease in patients with type 2 diabetes (T2D). Thus, we aimed to quantify the burden of liver disease, identify risk factors, and estimate attributable risks in patients with T2D. METHODS: We measured adjusted hazard ratios of liver disease progression to hepatocellular carcinoma and/or decompensated cirrhosis in a 2010-2020 retrospective, bicentric, longitudinal, cohort of 52,066 hospitalized patients with T2D. RESULTS: Mean age was 64±14 years and 58% were men. Alcohol use disorders accounted for 57% of liver-related complications and were associated with all liver-related risk factors. Non-metabolic liver-related risk factors accounted for 37% of the liver burden. T2D control was not associated with liver disease progression. The incidence (95% CI) of liver-related complications and of competing mortality were 3.9 (3.5-4.3) and 27.8 (26.7-28.9) per 1,000 person-years at risk, respectively. The cumulative incidence of liver disease progression exceeded the cumulative incidence of competing mortality only in the presence of well-identified risk factors of liver disease progression, including alcohol use. The incidence of hepatocellular carcinoma was 0.3 (95% CI 0.1-0.5) per 1,000 person-years in patients with obesity and it increased with age. The adjusted hazard ratios of liver disease progression were 55.7 (40.5-76.6), 3.5 (2.3-5.2), 8.9 (6.9-11.5), and 1.5 (1.1-2.1), for alcohol-related liver disease, alcohol use disorders without alcohol-related liver disease, non-metabolic liver-related risk factors, and obesity, respectively. The attributable fractions of alcohol use disorders, non-metabolic liver-related risk factors, and obesity to the liver burden were 55%, 14%, and 7%, respectively. CONCLUSIONS: In this analysis of data from 2 hospital-based cohorts of patients with T2D, alcohol use disorders, rather than obesity, contributed to most of the liver burden. These results suggest that patients with T2D should be advised to drink minimal amounts of alcohol. LAY SUMMARY: There is uncertainty on the burden of liver-related complications in patients with type 2 diabetes. We studied the risks of liver cancer and complications of liver disease in over 50,000 patients with type 2 diabetes. We found that alcohol was the main factor associated with complications of liver disease. This finding has major implications on the alcohol advice given to patients with type 2 diabetes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Mallet V, Parlati L, Martinino A, et al. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol. 2021. PMID: 34606913. doi:10.1016/j.jhep.2021.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。